Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis.
CareView Communications (OTC: CRVW.PK) develops, markets and operates high-speed data network systems that are deployed throughout healthcare facilities using the existing cable television infrastructure of the facility. The systems provide bedside, point-of-care video monitoring and recording as well as providing patients with entertainment, communications and education systems.
CorMedix Inc. (AMEX:CRMD-U) is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease. Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic problems which share the common trait of underlying oxidative stress and blood vessel malfunction (endothelial dysfunction).
iMedicor (OTC: VMCI.OB) builds portal-based, virtual work and learning environments primarily in healthcare and related industries. The Company's solutions allow physicians use the Internet to exchange and share patient medical information and to interact with pharmaceutical companies and review information on new drugs offered by these companies at a time of their choosing.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
Lixte Biotech (LIXT.OB) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options - such as certain types of brain cancer (glioblastoma multiforme or GBM, neuroblastoma, and medulloblastoma) and pancreatic cancer.
Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer based on the Company's PORxin and INxin technology platforms.
Quantum Immunologics (QI) is a privately held company that is dedicated to improving the treatment outcome and quality of life for cancer patients through the research, development, and commercialization of innovative, cost-effective therapeutic and diagnostic products. QI's scientific approach links the immunogenic and invasive properties of malignant cancers with a specific protein known as oncofetal antigen immature laminin receptor protein (OFA) that is uniquely expressed on cancer cells, but not found on normal cells outside of early fetal development.
Scivanta Medical Corporation (OTC: SCVM.OB) acquires and develops medical products that provide significant advantages over existing medical procedures and treatments. Scivanta has acquired exclusive worldwide rights to the Hickey Cardiac Monitoring System, a minimally invasive esophageal catheter that provides distinct economic and patient benefits compared with existing heart monitoring devices.
Unilife Corp. (NASDAQ: UNIS) is an emerging medical device manufacturer with business segments that include pre-filled syringes for pharmaceutical companies to deliver injectable medications, sharps safety devices for healthcare facilities, and contract manufacturing of medical devices.